Loading...
Nov 02, 2019
Drug | Mechanism | Route | Indication |
Afamelanotide | Melanocortin 1 receptor agonist | Subcutaneous | Phototoxicity in patients with erythropoietic protoporphyria |
Andexanet alpha | Bind to Factor Xa inhibitors | Intravenous | To reverse overdose of rivaroxaban and apixaban |
Apalutamide Darolutamide | Androgen receptor antagonist | Oral | Prostate carcinoma |
Avatrombopag Lusutrombopag | Thrombopoietin receptor agonist | Oral | Thrombocytopenia in patients with chronic liver disease |
Baloxavir marboxil | Inhibit viral replication by inhibiting Cap-dependent endonuclease activity of viral polymerase | Oral | Single dose treatment of Acute uncomplicated influenza |
Baricitinib | Janus Kinase inhibitor | Oral | Rheumatoid Arthritis |
Bremelanotide | Melanocortin receptor agonist | subcutaneous | Hypoactive sexual desire disorder in females |
Brexanolone | GABA-A modulator | Intravenous | Post partum depression |
Caplacizumab | vWF-directed antibody fragment | IV/SC | Thrombotic Thrombocytopenic Purpura |
Elagolix | GnRH antagonist | Oral | Pain associated with endometriosis |
Erenumab Fremanezumab Galcanezumab | Monoclonal antibody against CGRP | SC | Migraine prophylaxis |
Esketamine | Non-competitive NMDA antagonist | Intranasal | Treatment resistant depression |
Ibalizumab | MAb against CD4 | IV | HIV |
Inotersen | Antisense oligonucleotide against transthyretin mRNA | Subcutaneous | Polyneuropathy of hereditary transthyretin-mediated amyloidosis |
Istradefylline | Adenosine A2 receptor antagonist | Oral | Off episode in Parkinsonism |
Lasmiditan | 5HT1F agonist | Oral | Acute severe migraine |
Lofexidine | Alpha 2 agonist | Oral | To decrease opioid withdrawal symptoms |
Megalastat | Pharmacological chaperone for Alpha galactosidase | Oral | Fabry’s disease |
Moxidectin | Bind to Glutamate and GABA chloride channels | Oral | Onchocerciasis |
Netarsudil + Latanoprost | Netarsudil: Rho kinase inhibitor Latanoprost: PGF2 apha | Topical | Open angle glaucoma |
Patisiran | Small Interfering RNA based therapy against mutant transthyretin | Intravenous | Polyneuropathy in patients with transthyretin mediated amyloidosis |
Pitolisant | H3 antagonist/inverse agonist | Oral | Narcolepsy |
Pretomanid | Inhibit mycolic acid synthesis | Oral | For XDR and MDR TB (in combination with bedaquiline and linezolide) |
Ravulizumab | C5 Complement inhibitor | Intravenous | Paroxysomal Nocturnal Hemoglobinuria |
Romosozumab | MAb against sclerostin | Subcutaneous | Post-menopausal osteoporosis |
Selinexor | Selective inhibitor of nuclear export | Oral | Multiple myeloma Diffuse large B cell lymphoma |
Semaglutide | GLP-1 agonist | Oral | Type 2 diabetes mellitus |
Solriamfetol | DA and NA reuptake inhibitor | Oral | For excessive day time sleepiness in Obstructive sleep apnea and Narcolepsy |
Stiripentol | Increases GABAergic activity | Oral | Dravet Syndrome |
Tafenoquine | Free radical mediated killing of hypnozooites | Oral | Single dose radical cure of P. vivax malaria |
Tecovirimat | Inhibit formation of extracellular viral forms | Oral | Small pox |
Tenapanor | NHE-3 inhibitor | Oral | IBS with constipation |
Tolvaptan | Vasopressin V2 receptor antagonist | Oral | To slow kidney function decline in adult polycystic kidney disease |
Shweta has expertise in curating academic content and has assisted thousands of students in cracking various competitive exams and Owning their Dream.
Loading...